COMMUNIQUÉS West-GlobeNewswire

Loxo Oncology Reports Second Quarter 2018 Financial Results
09/08/2018
- LOXO-292 New Drug Application (NDA) Submission to FDA Expected in Late 2019 - - Updated Larotrectinib Duration of Response Data to be Reported at ESMO - - Larotrectinib NDA PDUFA date is November 26, 2018 - STAMFORD, [...]
HEXO Harvests First Plants in 250,000 sq. ft. Greenhouse Expansion
09/08/2018
GATINEAU, Quebec, Aug. 09, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (“HEXO” or the “Company”) (TSX:HEXO) continues to execute on its aggressive expansion at its Gatineau campus, with the first harvest of [...]
Récolte de premières plantes dans la serre agrandie de 250 000 pi2 d’HEXO
09/08/2018
GATINEAU, Québec, 09 août 2018 (GLOBE NEWSWIRE) -- La société Hydropothecary (« HEXO » ou la « Société ») (TSX: HEXO) poursuit une formidable expansion sur son campus de Gatineau, avec une toute première récolte dans sa [...]
Histogenics Corporation Announces Second Quarter 2018 Financial and Operating Results
09/08/2018
‒ Top-line Superiority Data from NeoCart ® Phase 3 Clinical Trial on Track for Third Quarter of 2018 ‒ ‒ Initiation of Phase 3 Clinical Trial in Japan Expected in Second Half of 2018 ‒ ‒ Expansion of Management Team in [...]
Jounce Therapeutics Reports Second Quarter 2018 Financial Results
09/08/2018
- Initiated enrollment in dose escalation cohorts of Phase 1/2 ICONIC trial of JTX-2011, in combination with ipilimumab and in combination with pembrolizumab - - Presented preliminary efficacy data for JTX-2011 at the [...]
Clementia Reports Second Quarter 2018 Operating Results and Pipeline Updates
09/08/2018
Patient Enrollment in Phase 3 MOVE Trial of Palovarotene for FOP On Track; Two Interim Data Analyses Expected in 2019 MONTREAL, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical [...]
Clementia présente ses résultats d’exploitation pour le deuxième trimestre de 2018 et fait le point sur son portefeuille de produits
09/08/2018
Le recrutement des patients pour l’essai de phase 3 MOVE sur le palovarotène pour le traitement de la fibrodysplasie ossifiante progressive (FOP) est sur la bonne voie; deux analyses intérimaires des données sont [...]
Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax
09/08/2018
Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potential Broadens development pipeline with an adenovirus 4/7 vaccine funded by the DoD for [...]
Cerecor Reports Second Quarter 2018 Financial Results
09/08/2018
BALTIMORE, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), an integrated biopharmaceutical company focused on pediatric healthcare and developing innovative therapies that make a difference in the lives [...]
RadNet Reports Second Quarter Financial Results to Include Record Revenue and Reaffirms Guidance Ranges
09/08/2018
Total Net Revenue increased 6.3% to $244.4 million in the second quarter of 2018 from $230.0 million in the second quarter of 2017 Adjusted EBITDA (1) increased 3.0% to $38.2 million in the second quarter of 2018 from $ [...]
Momenta Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
09/08/2018
CAMBRIDGE, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2018 and provided a corporate update. “The [...]
BeiGene Reports Second Quarter 2018 Financial Results
09/08/2018
CAMBRIDGE, Mass. and BEIJING, China, Aug. 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Release date of six-month interim report (Q2) 2018 and audio cast
09/08/2018
On Wednesday, 15 August 2018, ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) releases its interim report for the six months ended 30 June 2018. ALK will host a meeting for analysts and institutional investors that day at [...]
Nordic Transport Group Holding A/S announces preliminary result of takeover offer
09/08/2018
Company Announcement 9 August 2018 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH [...]
Gefion Group Investments A/S announces final result and withdrawal of takeover offer
09/08/2018
Company Announcement 9 August 2018 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH [...]
Active Biotech AB - Interim Report January - June 2018
09/08/2018
Second quarter in brief The company's partner NeoTX presented new preclinical data for ANYARA at the AACR Annual Meeting in Chicago The rights issue in April brought the company SEK 47.1 M Events after the end of the [...]
Notice of Nexstim Plc's Half-Yearly Report H1 2018
09/08/2018
Company announcement, Helsinki, 9 August 2018 at 9:00 AM Notice of Nexstim Plc's Half-Yearly Report H1 2018 Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or the " Company "), the targeted neuromodulation company [...]
Shire plc : Rule 2.9 Announcement
09/08/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 9 August 2018 [...]
Motif Bio to Present at Investor Events in August and September
09/08/2018
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will [...]

Pages